Baird Financial Group
ITCI

Baird Financial Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Baird Financial Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,474
Closed -$5.38M – 1847
2024
Q4 		$5.38M Buy
64,474
+16,711
+35% +$1.37M 0.01% 663
2024
Q3 		$3.49M Buy
47,763
+11,537
+32% +$867K 0.01% 796
2024
Q2 		$2.48M Buy
+36,226
New +$2.51M 0.01% 895
2020
Q3 		– Sell
-10,000
Closed -$257K – 1587
2020
Q2 		$257K Buy
+10,000
New +$202K ﹤0.01% 1351

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Baird Financial Group's ITCI Position: Q1 2025 in Review

Baird Financial Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 64,474 shares — an estimated $5.38M sold.

Baird Financial Group first reported a position in ITCI in Q2 2020 and held it in 4 quarters. The position peaked at $5.38M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Baird Financial Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Baird Financial Group sold 64,474 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $5.38M.
  • Baird Financial Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 4 quarters.
  • Baird Financial Group's Intra-Cellular Therapies Inc. position peaked at $5.38M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Baird Financial Group's 13F filing for Q1 2025, filed 15 May 2025.